JAKARTA — mClinica, a Singapore-headquartered health tech startup focused on the pharmaceutical industry, is planning to raise $20 million in its Series B round, just months after closing a bridge deal with U.S.-based Susquehanna International Group, a company executive told DealStreetAsia.
The bridge round was closed just before the coronavirus crisis struck the globe, crippling investments across sectors.
The funds raised in the bridge round was used to accelerate growth in Indonesia, said Farouk Meralli, founder and CEO of mClinica. The company is also in markets such as Philippines, Vietnam, Thailand, Malaysia and Cambodia.
Meralli said mClinica has grown significantly